Table 8. Studies reporting outcomes with perioperative chemotherapy.

Author (year)	Pathologic complete response	Pathologic downstaging	Median follow up after cystectomy	Survival outcomes after cystectomy	Major independent factor(s) other than histologic phenotype affecting response/outcomes analyzed	Comments
Ghoneim (20) (2011), n=38 (VH n=38)	–	–	17 months	Median survival of the patients who had and had not received perioperative cisplatin-based chemotherapy was 23 months (95% CI: 9–32) and 46 months (95% CI: 12-69), respectively. All patients who received perioperative cisplatin-based chemotherapy died of metastatic disease. 5-year OS rate was 40% (95% CI: 16–64)	–	–
Patients with micropapillary UC treated with perioperative chemotherapy

VH, variant histology; UC, urothelial carcinoma; OS, overall survival.